This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

This product is a part of intravenous nutrition, used to supplement the daily physiological needs of various water-soluble vitamins so that the body's relevant biochemical reactions can proceed normally.

This product is a non-steroidal anti-inflammatory analgesic, a thiazide derivative, with strong analgesic and anti-inflammatory effects. Its mechanism of action includes: 1. Inhibiting the synthesis of prostaglandins by inhibiting the activity of cyclooxygenase (COX); however, it does not inhibit the activity of 5-lipid oxidase, so it does not inhibit the synthesis of leukotrienes, nor does it shunt arachidonic acid to the 5-lipid oxidase pathway. 2. Activating the opioid neuropeptide system to exert a central analgesic effect.

1 Anti-tumor effect: (1) It shows high anti-tumor activity against mouse leukemia L-1210. (2) It has a wide anti-tumor spectrum against mouse transplanted tumors. It shows excellent effects on lymphocytic leukemia L1210, granulocytic leukemia C-1498, plasmacytoma X-5563 (ascites type), Ehrlich's ascites carcinoma, and dural sarcoma MS-147. (3) This agent has a life-extending effect on mice with lymphocytic leukemia L1210 and methylcholanthrene-induced malignant glioma cells transplanted into the brain. 2 Mechanism of action: The main mechanism of action is to alkylate the DNA in the cell and reduce the molecular weight of the DNA, thereby inhibiting DNA synthesis.

This product exerts its cytotoxic effect by inhibiting topoisomerase I, making DNA unable to replicate and causing irreversible DNA chain damage, thereby leading to cell death.